For research use only. Not for therapeutic Use.
Fosinopril Sodium is a phosphinic acid-containing ACE (angiotensin-converting enzyme) inhibitor that is effective in the treatment of hypertension. It is a prodrug that is converted to its active metabolite fosinoprilat.
| Catalog Number | A001120 |
| CAS Number | 88889-14-9 |
| Synonyms | Q28555 |
| Molecular Formula | C30H45NO7P • Na |
| Purity | ≥95% |
| Target | Apoptosis |
| Solubility | DMSO |
| Storage | 3 years -20C powder |
| InChIKey | TVTJZMHAIQQZTL-TXDYNIFHSA-M |
| Reference | </br>1:[Protective effect of fosinopril sodium pretreatment combined with ischemic postconditioning on rat heart underwent myocardial ischemia/reperfusion injury]. Zhang DW, Zhang L, Liu JG, Wang CL, Shi DZ, Chen KJ.Zhonghua Xin Xue Guan Bing Za Zhi. 2010 Jul;38(7):633-7. Chinese. PMID: 21055289 </br>2:Monitoring of fosinopril sodium impurities by liquid chromatography-mass spectrometry including the neural networks in method evaluation. Jancić B, Medenica M, Ivanović D, Janković S, Malenović A.J Chromatogr A. 2008 May 2;1189(1-2):366-73. Epub 2007 Dec 4. PMID: 18154978 </br>3:Microemulsion liquid chromatographic method for characterisation of fosinopril sodium and fosinoprilat separation with chemometrical support. Janci B, Medenica M, Ivanović D, Malenović A, Marković S.Anal Bioanal Chem. 2005 Oct;383(4):687-94. Epub 2005 Sep 30. PMID: 16195875 </br>4:A new treatment forInterdialytic hyperkalemia – the use of fosinopril sodium. Mousa D, Rassoul Z, Popovich W, Hassan A, Margate V, Hawas F, Suleiman M, Al Khader A.Am J Nephrol. 1999;19(3):395-9. PMID: 10393377 </br>5:Effect of fosinopril sodium on early carotid atherosclerosis in diabetic patients with hypertension. Migdalis IN, Gerolimou B, Kozanidou G, Hatzigakis SM, Karmaniolas KD.J Med. 1997;28(5-6):371-80. PMID: 9604795 </br>6:The determination of palladium in fosinopril sodium (monopril) by ICP-MS. Lewen N, Schenkenberger M, Larkin T, Conder S, Brittain HG.J Pharm Biomed Anal. 1995 Jun;13(7):879-83. PMID: 8562611 </br>7:Aggregation behavior of fosinopril sodium–a new angiotensin-converting enzyme inhibitor. Wang Z, Morris KR, Chu B.J Pharm Sci. 1995 May;84(5):609-13. PMID: 7658352 </br>8:Quantitative analysis of fosinopril sodium by capillary zone electrophoresis and liquid chromatography. Lozano R, Warren FV Jr, Perlman S, Joseph JM.J Pharm Biomed Anal. 1995 Feb;13(2):139-48. PMID: 7766720 </br>9:A lamellar liquid crystal with fosinopril sodium. Friberg SE, Moaddel T, Morris KR, Abramowitz R, Amsberry KL.J Pharm Sci. 1994 May;83(5):677-9. PMID: 8071820 </br>10:Angiotensin-converting enzyme inhibition with fosinopril sodium in the prevention of restenosis after coronary angioplasty. Desmet W, Vrolix M, De Scheerder I, Van Lierde J, Willems JL, Piessens J.Circulation. 1994 Jan;89(1):385-92. PMID: 8281674 |
